Cargando…

How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?

BACKGROUND: For localized prostate cancer (PCa), radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality. Contemporary studies contained the elderly people; analyses focusing on patients over 75 years of age were still lacking. METHOD: In the Surveil...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Kun, Qiu, Shi, Li, Jiakun, Zheng, Xiaonan, Tu, Xiang, Liao, Xinyang, Yang, Yan, Yang, Lu, Wei, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601593/
https://www.ncbi.nlm.nih.gov/pubmed/31066510
http://dx.doi.org/10.1002/cam4.2221
_version_ 1783431317968388096
author Jin, Kun
Qiu, Shi
Li, Jiakun
Zheng, Xiaonan
Tu, Xiang
Liao, Xinyang
Yang, Yan
Yang, Lu
Wei, Qiang
author_facet Jin, Kun
Qiu, Shi
Li, Jiakun
Zheng, Xiaonan
Tu, Xiang
Liao, Xinyang
Yang, Yan
Yang, Lu
Wei, Qiang
author_sort Jin, Kun
collection PubMed
description BACKGROUND: For localized prostate cancer (PCa), radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality. Contemporary studies contained the elderly people; analyses focusing on patients over 75 years of age were still lacking. METHOD: In the Surveillance Epidemiology and End Results (SEER) database (2004‐2015), people over 75 years of age with cT2 stage were selected in our research. Multivariable Cox proportional hazard models were used to analyze cancer‐specific mortality (CSM) and overall mortality (OM) after adjustment. The propensity score matching was performed to assume the randomization. An instrument variate (IVA) was used to calculate the unmeasured confounders. RESULTS: Radical prostatectomy is superior to RT in OM and CSM after adjustment for covariates (HR = 0.54, 95% CI = 0.47‐0.62, P < 0.001 and HR = 0.30, 95% CI = 0.20‐0.45, P < 0.001, respectively). The cox model after matching indicated similar consequence (OM: HR = 0.53, 95% CI = 0.46‐0.62, P < 0.001; CSM: HR = 0.27, 95% CI = 0.17‐0.43, P < 0.001). In the IVA‐adjusted model, the effect of treatment changed slightly (OM: HR = 0.65, 95% CI = 0.54‐0.78, P < 0.001; CSM: HR = 0.21, 95% CI = 0.12‐0.37, P < 0.001). Subgroup analyses showed that for patients with GS = 7, those received RP obtained the highest risk decline for overall death (HR = 0.41, 95% CI = 0.32‐0.52); and for patients with younger age, those received RP obtained the highest risk decline for CSM (HR = 0.11, 95% CI = 0.01‐0.52). CONCLUSION: Patients over 75 years of age with cT2 stage will obtain more benefit from RP compared with RT, especially for patients with GS = 7 and younger age.
format Online
Article
Text
id pubmed-6601593
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66015932019-07-22 How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? Jin, Kun Qiu, Shi Li, Jiakun Zheng, Xiaonan Tu, Xiang Liao, Xinyang Yang, Yan Yang, Lu Wei, Qiang Cancer Med Clinical Cancer Research BACKGROUND: For localized prostate cancer (PCa), radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality. Contemporary studies contained the elderly people; analyses focusing on patients over 75 years of age were still lacking. METHOD: In the Surveillance Epidemiology and End Results (SEER) database (2004‐2015), people over 75 years of age with cT2 stage were selected in our research. Multivariable Cox proportional hazard models were used to analyze cancer‐specific mortality (CSM) and overall mortality (OM) after adjustment. The propensity score matching was performed to assume the randomization. An instrument variate (IVA) was used to calculate the unmeasured confounders. RESULTS: Radical prostatectomy is superior to RT in OM and CSM after adjustment for covariates (HR = 0.54, 95% CI = 0.47‐0.62, P < 0.001 and HR = 0.30, 95% CI = 0.20‐0.45, P < 0.001, respectively). The cox model after matching indicated similar consequence (OM: HR = 0.53, 95% CI = 0.46‐0.62, P < 0.001; CSM: HR = 0.27, 95% CI = 0.17‐0.43, P < 0.001). In the IVA‐adjusted model, the effect of treatment changed slightly (OM: HR = 0.65, 95% CI = 0.54‐0.78, P < 0.001; CSM: HR = 0.21, 95% CI = 0.12‐0.37, P < 0.001). Subgroup analyses showed that for patients with GS = 7, those received RP obtained the highest risk decline for overall death (HR = 0.41, 95% CI = 0.32‐0.52); and for patients with younger age, those received RP obtained the highest risk decline for CSM (HR = 0.11, 95% CI = 0.01‐0.52). CONCLUSION: Patients over 75 years of age with cT2 stage will obtain more benefit from RP compared with RT, especially for patients with GS = 7 and younger age. John Wiley and Sons Inc. 2019-05-08 /pmc/articles/PMC6601593/ /pubmed/31066510 http://dx.doi.org/10.1002/cam4.2221 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Jin, Kun
Qiu, Shi
Li, Jiakun
Zheng, Xiaonan
Tu, Xiang
Liao, Xinyang
Yang, Yan
Yang, Lu
Wei, Qiang
How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
title How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
title_full How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
title_fullStr How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
title_full_unstemmed How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
title_short How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
title_sort how to choose proper local treatment in men aged ≥75 years with ct2 localized prostate cancer?
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601593/
https://www.ncbi.nlm.nih.gov/pubmed/31066510
http://dx.doi.org/10.1002/cam4.2221
work_keys_str_mv AT jinkun howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT qiushi howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT lijiakun howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT zhengxiaonan howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT tuxiang howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT liaoxinyang howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT yangyan howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT yanglu howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer
AT weiqiang howtochooseproperlocaltreatmentinmenaged75yearswithct2localizedprostatecancer